Index

Absorption, distribution, metabolism and excretion (ADME) trial, 184
Acupuncture, 147
Acute lymphoblastic leukaemia, 88
Adjuvant analgesics, 143–144
Amityryptiline, 144
Anticoagulation therapy, 99
Anticonvulsant medication, 98–99
Antidepressant medication, 166
Anxiety, 34
APC gene, 27
Apopotosis, 3
Association of British Insurers (ABI), 41
Astrocytes, 88
Astrocytomas, 89
Autosomal dominant disorder, 26
Autosomal dominant inheritance, 33–34
factors affecting, 33
Autosomal dominant tumour suppressor gene, 27
Autosomal recessive inheritance, 33, 34
Autosomes, 26, 33
Better cancer care, 18
Blood–brain barrier, 98
Body’s pain detection system, 124
Brachytherapy, 95
Brain dysfunction, 89–90
Brain tumours. See Primary malignant brain tumours
Breakthrough pain, 129
management, 139
Breast cancer, 27
family guidelines, 35, 36
Cancer genetics
autosomal dominant inheritance, 33–34
autosomal recessive inheritance, 34
case study, 42–43
ethical issues, 41
family history collection methods, 33
family tree, construction, 30–32
genetic risk assessment, 34–35
 genetic testing, 40
and insurance, 41
guidelines for health professionals, 35–36

Breast Cancer Care, 172
British Association of Cancer United Patients (BACUP), 16
British Society of Gastroenterology and Association of Coloproctology (BSGAC), 35
Cachexia, 164
Cancer Caring Centre, 13
Cancer clinical trials
history of, 180, 181
nurse–patient relationship, 187–191
communication, importance, 187
emotional intelligence, 189–190
emotional labour in, 188–189
nurse as cancer nursing researcher, 190–191
phase I trials, 183–185
phase II trials, 185–186
phase III trials, 186–187
phase IV trials, 187
role of educator, 185

Better cancer care, 18
Blood–brain barrier, 98
Body’s pain detection system, 124
Brachytherapy, 95
Brain dysfunction, 89–90
Brain tumours. See Primary malignant brain tumours
Breakthrough pain, 129
management, 139
Breast cancer, 27
family guidelines, 35, 36
Cancer genetics
autosomal dominant inheritance, 33–34
autosomal recessive inheritance, 34
case study, 42–43
ethical issues, 41
family history collection methods, 33
family tree, construction, 30–32
genetic risk assessment, 34–35
 genetic testing, 40
and insurance, 41
guidelines for health professionals, 35–36
Cancer genetics (Continued)

- individuals identification at risk of genetic conditions
- confirmation of cancer, 29–30
- integration in healthcare, 24
- rare cancer syndromes, 41
- referring individuals to specialist sources
- consent for referral, 37–39
- surveillance screening, 39
- relevance to nurse’s practice, 25–28
- breast and ovarian cancer, 26–27
- cancer syndromes involving breast and colon, 28
- colorectal cancer, 27–28

Cancer nursing

- caring, 196–199, 204–208
- caring relationship, 198–199
- emotional intelligence, 202–204
- emotional work, 199–202
- management of feelings, 200–202

Cancer pain, 122–123. See also Total pain, concept of

- case study, 149–152
- management of, 130–131

Cancer reform strategy, 10, 17, 172

Cancer-related fatigue, 159

- assessing and measuring, 161–162
- Fatigue Symptom Inventory, 161
- Multi-dimensional Fatigue Inventory, 161
- Revised Piper Fatigue Scale, 161
- causes and mediators, 162–165
- caused by cancer itself, 164–165
- depression and fatigue, 165
- role of cytokines, 164
- treatment-related fatigue, 162–163
- define, 160
- experience of, 160–161
- management, 165
- non-pharmacological methods, 167–171
- pharmacological methods, 165–167

Cancers

- genetic predisposition, 29
- as journey, 9–11, 15–18
- linear and rollercoaster cancer, 10–11
- reflections on, 19–20
- stories and narratives, 18–19
- wounded healers and, 19
- life after treatment, 13–15
- cancer recurrence, 14–15
- end of survival journey, 15
- lifetime risk, 27
- as metaphor, 9
- treatment journey, 11–13

Cancer surgeon, 109

- joys and heartaches, 118–119
- monitoring progress, in cancer surgery, 119–120
- surgical techniques, changes, 119
- and patient newly diagnosed with cancer, 112
- referral of patient, 112–113

Cancer surgery

- principles, 110
- surgeon and cancer recurrence, 111
- surgeon and palliation, 111–112
- surgeon and potentially curative surgery, 110–111
- recovering from, 115
- follow-up, 116
- palliative care, 116

Carcino-embryonic antigen (CEA), 216

Caring, 196–199, 204–208

- definition, 197
- emotional aspects, 250
- nature, and quality of, 198
- types of, 196

Carmustine implants, 94

Cell suicide. See Apoptosis

Cerebral spinal fluid, 89

Chemical carcinogens, 88

Chemo-radiation, 97

Chemotherapeutic agents, effects, 51

Chemotherapy, 147, 220

Childbearing woman, with cancer, 48

- cancer, childbearing and conflicts
- decision making, 51
- interventions, 51
- timing of birth, 51
- implications for midwife decisions, 54
- organisational issues, 54–55
- place of care, 56
- provision of care, 54
- risk status, 55
- interaction with pregnancy, and childbirth, 50
- significance, 49–50
support for, 56–60
midwife’s role in, 58–59
Clinical nurse specialist, 116, 117
role, from perspective of cancer surgeon, 117
advocate for hospital, 117
facilitating research, 118
follow-up care after discharge, 118
friend and advocate to patient, 117
genetic basis of cancer, understanding, 118
Clinical trials research nurse. See also Cancer clinical trials
competencies, 182
preparation, 181–183
Colorectal cancer, 27–28
Complementary therapies, in cancer patients, 147
Computed axial tomography (CAT), 16
Corticosteroid medication, 99, 166
case study, 167
Craniotomy, 94
Cytokines, 164

Decision making process, 51–52
Deoxyribonucleic acid (DNA), 25, 26, 64, 214, 220
damage, 3
mismatch repair (MMR) genes, 28, 214
repair genes, 3
structure, 2
Distraction techniques, 148, 170
Dukes system, of pathological staging, 216

Edmonton Fatigue Framework, 173
Electro-acupuncture-induced analgesia, 147
Emotional distress, 125–126
Emotional intelligence, 203, 204
Energy conservation, for patient, 169
case study, 169–170
tips, in managing cancer-related fatigue, 169
Ependymal cells, 88
Exercise, in management of cancer, 167–169
case study, 168
Expert Patient Programme, 173
External beam radiotherapy, 95, 98
Faecal occult blood testing (FOBT), 214
Familial adenomatous polyposis (FAP), 36, 88, 214
attenuated FAP (AFAP), 27
hereditary nonpolyposis colorectal cancer (HNPCC), 27, 28
MUTYH-associated polyposis (MAP), 27
Family-based oncology, 12
Family tree, construction, 30–32
recessive family tree, 32
symbols and relationship lines, 31
Fatigue diary, 169. See also Cancer-related fatigue
Fentanyl, 139
Frameworks, standards of palliative care
gold standards framework (GSF), 233–235
case study, 233–236
liverpool care pathway for the dying patient (LCP), 174, 240–244
potential benefits and challenges, 242
summary of, 240–241
person-centred care, 236–238
case study, 239

Gabapentin, 139, 144
Gag reflex test, 70
Gamma-aminobutyric acid (GABA), 144
Genetic counsellor, 29
Genetic disorders, 26
Genetic testing
availability, 40
and insurance, 41
Glioblastoma, 89, 93, 96
Glioma grading system, 88
Goleman’s theory, 190
Good clinical practice (GCP), 182
Gross national product (GNP), 17

Haemopoietic growth factors, 167
Healthcare professionals, 12, 14, 16, 18, 19
ability of, 15
guidelines for, 35
and patients, resources for, 38
Herbal medication, 147
Hereditary nonpolyposis colorectal cancer (HNPCC), 27, 28, 35, 39, 214. See also Lynch syndrome
Heterozygous germ line mutation, 214
Index

Homeopathic medication, 148
Homeostatic mechanisms, 3
Hope-inspiring nursing, 11
Hope-sustaining strategies, 231
Hormone therapy, 162
Hot stone therapy, 147
5HT3 receptor antagonist, 16
Human genome project (HGP), 26
Hyoscine, 144
Hypothalamic–pituitary–adrenal (HPA) axis, 162

Immunohistochemistry (IHC)
  screening, 35
  staining, 28
Incident pain, 130
  management, 139
Intensity modulated radiotherapy (IMRT), 94
Interpersonal intelligence, 202
Interventions, 51
Intracranial pressure, 89

Juvenile polyposis syndrome (JPS), 28

Karnofsky performance (KPS) rating scale, 91
Ketamine, 139, 144

Lomustine, 98
Lynch syndrome, 27

Macmillan Cancer Support, 169
Maternal autonomy, principle, 53
Metastases
  blood-borne, 216
  bone, 139, 144, 146, 147, 149–151
  concept, via bloodstream, 2
  diseases
    following curative resection, 14
    management, 14
  hepatic, 218
  liver, 144
  lung, 149
  placental barrier minimising, risk of, 50
  regional lymph node, 216
  spinal, 151
  staging classification, 114
Methicillin-resistant Staphylococcus aureus (MRSA), 119
Methylphenidate, 166
Microsatellite instability (MSI), 35
Mismatch repair genes (MMR), 28
Modified Eastern co-operative oncology group grading system, 70
Morphine, 141, 143
Mucositis. See Oral mucositis
Multidisciplinary team, 113–114
  preparing for cancer surgery, 114–115
Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), 74
Mutation analysis, 40
MUTYH-associated polyposis (MAP), 27, 28

Naïve trusting, 188
Naloxone, 147
National cancer institute common toxicity criteria (NCI-CTC), 66
National Genetics Education and Development Centre (NGEDC), 24
National health service (NHS), 6, 16, 24, 37, 40, 112, 147, 181
National institute for health and clinical excellence (NICE), 87, 92, 217
  CG 41 guideline, 35
Neurofibromatosis, 88
Neuropathic pain, specific challenges, 145
  central neuropathic pain, 146
  peripheral neuropathic pain, 145–146
Nociceptive pain, 124
Nominal group technique (NGT), 77
  items generated by, 78
  steps involved, 77
Nuclear factor kappa-B (NF-kB), 64

Oligodendrocytes, 88
Oncogenes, 3
One-page assessment tool, 74
Opioid analgesics
  administration, changing route of, 142–143
  side effects, 140
  toxicity, 140–141
    management, 141–142
Optimal pain assessment, 127–129
Oral assessment guide (OAG), 67–69, 72, 75
  challenges, in children, 73
  criticism of, 71
Oral mucositis
children’s international mucositis evaluation scale (ChIMES), 71
content validity and acceptability, understandability, 80
creation of assessment instrument, 78–79
establishing literature-based items for, 75–77
generating items for, 77–78
literature review, 71–72
using focus group methodology, 73–75
measurement in adults
assessment tools, 65–68
NCI-CTC version 3 scoring criteria, 66
oral mucositis assessment scale (OMAS), 67, 68, 70, 71, 76
oral mucositis daily questionnaire (OMDQ), 67, 76
oral mucositis index (OMI), 67, 74–76
oral mucositis rating scale (OMRS), 67
utilisation of assessment tools, 68
WHO scoring criteria, 66
measurement in children, 68–70
pathophysiology
healing, 65
initiation, 64
primary damage response, 64–65
signal amplification, 65
ulceration, 65
related symptoms, 63
Oramorph®, 133, 139
Ovarian cancer, 26
Oxycodone, 132, 133, 139
OxyContin®, 133
Pain empathy, 125
Pain pathways, 124–125
Pain-relieving measures, 146–148
cancer therapies, and management of pain, 146–147
complementary, and alternative therapy, 147–148
at end of life, 148
Palliative care, 102–103, 229. See also Caring guidelines, 243
Papilloedema, 89
Parenteral lidocaine, 144
Patient’s care pathway, 25
Personal value system, 54
Person-centred care, 236–239
case study, 239
Peutz–Jeghers syndrome, 28
Pregabalin, 144, 146
Primary malignant brain tumours, 87
aetiology, 88–89
clinical manifestations, 89
brain dysfunction, 89–90
intracranial pressure, 89
diagnostic investigations, 92
histopathology, 93
neuro-imaging, 92–93
grading system, by WHO, 88
impact of diagnosis, 92
incidence, 87–88
medications, 98
anticoagulation therapy, 99
anticonvulsant medication, 98–99
corticosteroids, 99
quality of life, 100–101
somnolence syndrome, following radiotherapy, 96–97
palliative care, 102–103
prognostic factors, 90–91
KPS rating scale, 91
WHO performance status criteria, 91
symptoms, 89
treatment, 93
biopsy, 93–94
carmustine implants, 94
chemo-radiation, 97
chemotherapy, 98
craniotomy, 94
radiotherapy, 94–96
skin care, 96
stereotactic radiotherapy, 97–98
surgery, 93
Primary malignant gliomas, 88
Prince’s Foundation for Integrated Health, 147
Procarbazine, 98
Progestational steroids, 167
Prostate cancer patients, 173
Psychological distress, 125
Psychostimulants, 165
Quality of life (QOL), 73, 74, 100, 101
Index

Radiation therapy oncology group (RTOG), 67, 68, 74
Radiotherapy, 94–95, 146, 218–220
    clinical indications, 219
Reactive oxygen species (ROS), 64
Rectal cancer, 212
    assessment structure for bowel function, 223
    case study, 225
    incidence, risk factors and aetiology, 212–215
    management and treatment, 212, 217
    chemotherapy, 220
    local recurrence, 221–222
    radiotherapy, 218–220
    surgery, 218
    treatment effects, 220–221
    percentage distribution of cases, 213
    presenting features, diagnosis and staging, 215–217
    self-care and supportive interventions, 222–224
    staging of, 217
    survival rates, 217
Reflexology, 147
Regional cancer genetic services, 37
Reiki, 147
Research coordinator, 181
Resilience, 13
Revised Piper Fatigue Scale, 161
Ritalin®, 166
Royal college of nursing (RCN), 182
Scottish Government Health Department (SGHD), 213
Scottish Intercollegiate Guidelines Network (SIGN), 35, 140, 217
Scottish Research Nurse and Coordinators Network (SRNCN), 190
Self-care behaviour (SCB), 68
Self-management interventions, 224
Sleep hygiene techniques, 170
Social aspects of pain, 125
Somnolence syndrome, 96
Sphincter-saving surgery, 221
Spiritual pain, 125
Stereotactic biopsy, 93–94
Steroid therapy, 51
Stress, 208
    definition, 208
    incontinence, 224
    induced weight loss, 11
    related emotions, 56
    related illness, 189
Strong opioids, 132
    misconceptions about, 142–143
    properties, 134–138
Suicide genes, 3
Surgery, as treatment regime for cancer, 110.
    See also Cancer surgery
Surveillance screening, 39
    frequency, 39
    modalities, 39
Surviving cancer, living life, 173
Tinea capitis, 88
Tom’s support network, 233
Total pain, concept of, 123–125
    experience and perception, 124
    pain empathy, 125
    pathways, 124–125
    reality of, 126
    social aspects, 125
Tuberous sclerosis, 88
Tumour necrosis factor (TNF), 64
Tumour suppressor genes, 3, 26
UK National Health Service, 57
Union Internationale Contre Le Cancer (UICC), 216
Vincristine, 98
Western Consortium for Cancer Nursing Research (WCCNR) scales, 68
WHO analgesic ladder, for cancer pain, 130
X chromosome, 26
X-rays, 95